Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
CONCLUSIONS: According to the results of the present study we suggest advancing RSV prophylaxis in Israel from 1 November to mid-October. The precise palivizumab-eligible categories should be reconsidered.
PMID: 30772962 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
More News: Bronchiolitis | Children | General Medicine | Intensive Care | Israel Health | Microbiology | Middle East Health | Pediatrics | Respiratory Medicine | Study